| November 13, 2014 | ISSUE NUMBER 377 VOL 4 |
|
Special Feature
Pharm Exec’s 2015 Pipeline Report
This year's pipeline report checks in on the emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? ...Read more
AstraZeneca are seeking to appoint a Vice President R&D Supply Chain. Joining our Pharmaceutical Development leadership team you will hold accountability for the provision of an integrated end-to-end global supply chain organisation that sources, makes and delivers material for phase I-IV clinical trial studies.
This rare opening presents a significant opportunity to make a high profile contribution to the leadership, strategic direction
and growth of Pharmaceutical Development within
AstraZeneca.
 Learn more
Regulatory
New Republican Congress Will Tackle Health Reform, Biomedical Innovation, Tax Policy
As the Obama Administration comes to terms with last week’s elections delivering a clear blow to its policies, a first order of business next year for Republican leaders is legislation to repeal the Affordable Care Act (ACA). Such a measure will be largely symbolic; there are many ACA features that even conservatives applaud. Jill Wechsler reports ...Read more
Regulatory
Medicare Part B Data: Handle with Care
CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny by policy makers and health sector critics for high-billing doctors and pharma manufacturers. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look ...Read more
Proceed with Confidence. Understanding Your Molecule’s Full Potential During Proof of Concept
Demonstrating your molecule’s proof of concept is an important developmental milestone. If you can show compelling and valid data supporting safety, efficacy and commercial potential, you will feel confident in your decision to move forward to the next, more costly, development phase.  Learn more
Event
Merck KGaA CEO Raises Ire on IP and Access to Medicines
Speaking as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in New York last week, Merck KgaA’s Stefan Oschmann called for more health innovation through local entrepreneurship and strongly denounced the argument that intellectual property is a hindrance to access to medicines
...Read more
Event
The Top Medical Innovations for 2015
The Cleveland Clinic once again ended its Medical Innovation Summit with a list of 10 advances most likely to have a major impact on improving patient care in 2015. The 110 voting Cleveland Clinic physicians and scientists share their excitement with Pharm Exec, picking a few choice items from the Top Ten list
...Read more
|
|
|
|
 //President and CEO of Sangamo BioSciences (Richmond, CA) was named as Chairman of the Alliance for Regenerative Medicine (ARM, Washington, DC)//Alexion Pharmaceuticals (Cheshire, CT) announced the planned retirement of company co-founder Stephen Squinto, Ph.D., effective January 1, 2015.//James M. DeTore joined bluebird bio (Cambridge, MA) as Chief Financial Officer.//TetraLogic Pharmaceuticals Corporation (Malvern, PA) appointed Mary Ann Gray, Ph.D., and Michael D. Kishbauch as Class I Directors to fill two board slots that have been vacant since January 2014.// |
|
|
|
|
|
 |
|
|
|
 |
 |
Which of the following is your most important upcoming initiative?
|
|
|
|
